Innovations in High-Risk MDS: Expert Insights with Dr. Jacqueline Garcia image

Innovations in High-Risk MDS: Expert Insights with Dr. Jacqueline Garcia

May 27, 2026
02:00PM - 03:00PM EDT
Online Event
Overview

Join Dr. Jacqueline Garcia of the Dana-Farber Cancer Institute for an essential update on the rapidly evolving treatment landscape for High-Risk MDS. This webinar will break down the latest clinical innovations, including promising combination therapies and targeted oral treatments, into clear and actionable insights. Whether you are newly diagnosed or exploring new options, you’ll gain the expert knowledge needed to navigate high-risk care with confidence.

Agenda
2:00 PM
Introduction
Dalton Bean

Dalton introduces the agenda for the event and our featured speaker Dr. Jacqueline Garcia

2:35 PM
Questions and Answers
Audience

Come with your questions and experiences to share with the group!

2:05 PM
Presentation
Jaqueline Garcia, MD

Dr. Garcia talks about high risk MDS

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Jaqueline Garcia, MD

Jaqueline Garcia, MD

Dr. Jacqueline S. Garcia is a medical oncologist in the Adult Leukemia Program at the Dana-Farber Cancer Institute. She graduated from University of Illinois at Chicago College of Medicine and completed her internship and residency training in Internal Medicine at the University of Chicago. She next completed Hematology and Oncology Fellowship training at Stanford University. Dr. Garcia’s research focus is on the design and execution of scientifically-based early phase clinical and proof-of-concept studies in advanced myeloid malignancies, including myelodysplastic syndromes, myelofibrosis and acute myeloid leukemia. Much of her research centers on identifying novel therapeutic opportunities to leverage the anti-apoptotic pathway in chemoresistant leukemia and developing investigator-initiated trials.  Her research is supported by awards from the National Institutes of Health/National Cancer Institute, Leukemia and Lymphoma Society, and Conquer Cancer Foundation.